Balaxi Pharmaceuticals Limited(IN:BALAXI)
₹31.65+5.18 (+19.57%)
IN:BALAXI
Balaxi Pharmaceuticals Limited financials statements
₹31.65
At close:+5.18 (+19.57%)
Want to see IN:BALAXI full AI Analyst Report?
Balaxi Pharmaceuticals Limited (BALAXI) Ratios
0 Followers
Balaxi Pharmaceuticals Limited Ratios
IN:BALAXI's free cash flow for Q4 2026 was ₹0.00. For the 2026 fiscal year, IN:BALAXI's free cash flow was increased by ₹0.00 and operating cash flow was ₹0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.51 | 4.45 | 3.88 | 3.64 | 2.23 |
| Quick Ratio | 4.51 | 4.45 | 2.36 | 1.67 | 0.67 |
| Cash Ratio | 0.44 | 0.72 | 1.15 | 0.53 | 0.11 |
| Solvency Ratio | 0.04 | 0.34 | -0.01 | 0.84 | 0.76 |
| Operating Cash Flow Ratio | -0.25 | -0.69 | 0.09 | 0.11 | 0.54 |
| Short-Term Operating Cash Flow Coverage | -0.25 | -1.24 | 0.28 | 0.57 | 9.39 |
| Net Current Asset Value | ₹ 627.07M | ₹ 1.64B | ₹ 1.53B | ₹ 1.37B | ₹ 776.97M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.17 | 0.08 | 0.06 | 0.02 |
| Debt-to-Equity Ratio | 0.23 | 0.23 | 0.10 | 0.07 | 0.03 |
| Debt-to-Capital Ratio | 0.19 | 0.19 | 0.09 | 0.07 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.08 | 0.08 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.35 | 1.34 | 1.28 | 1.31 | 1.56 |
| Debt Service Coverage Ratio | 0.10 | 0.81 | 2.13 | 4.39 | 13.01 |
| Interest Coverage Ratio | 1.36 | 12.40 | 27.86 | 117.26 | 355.31 |
| Debt to Market Cap | 0.65 | 0.14 | 0.03 | 0.02 | 0.01 |
| Interest Debt Per Share | 11.29 | 10.19 | 4.00 | 2.62 | 0.72 |
| Net Debt to EBITDA | 5.79 | 0.46 | -0.94 | -0.25 | -0.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 41.73% | 43.92% | 46.67% | 39.83% | 29.99% |
| EBIT Margin | 1.94% | 9.93% | 18.05% | 17.43% | 19.87% |
| EBITDA Margin | 2.73% | 10.58% | 18.92% | 17.95% | 20.05% |
| Operating Profit Margin | 1.94% | 12.60% | 19.37% | 17.43% | 18.01% |
| Pretax Profit Margin | 1.94% | 9.93% | 0.84% | 16.92% | 19.51% |
| Net Profit Margin | 0.52% | 8.68% | -0.99% | 13.66% | 17.06% |
| Continuous Operations Profit Margin | 0.52% | 8.68% | -0.99% | 13.66% | 17.06% |
| Net Income Per EBT | 26.77% | 87.45% | -118.44% | 80.75% | 87.41% |
| EBT Per EBIT | 100.00% | 78.77% | 4.31% | 97.09% | 108.37% |
| Return on Assets (ROA) | 0.42% | 8.08% | -0.92% | 19.18% | 27.01% |
| Return on Equity (ROE) | 0.57% | 10.82% | -1.19% | 25.13% | 42.11% |
| Return on Capital Employed (ROCE) | 1.74% | 14.23% | 22.89% | 31.43% | 44.44% |
| Return on Invested Capital (ROIC) | 0.42% | 11.12% | -24.95% | 24.00% | 37.64% |
| Return on Tangible Assets | 0.47% | 8.84% | -1.03% | 21.52% | 31.28% |
| Earnings Yield | 1.66% | 6.77% | -0.42% | 8.23% | 12.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.01 | 2.61 | 4.33 | 6.43 | 10.14 |
| Payables Turnover | 7.50 | 10.54 | 4.43 | 5.86 | 3.98 |
| Inventory Turnover | 0.00 | 0.00 | 1.57 | 1.93 | 1.98 |
| Fixed Asset Turnover | 5.57 | 7.95 | 14.80 | 17.69 | 53.70 |
| Asset Turnover | 0.81 | 0.93 | 0.93 | 1.40 | 1.58 |
| Working Capital Turnover Ratio | 1.79 | 1.68 | 1.63 | 3.08 | 4.08 |
| Cash Conversion Cycle | 133.31 | 105.38 | 234.97 | 183.86 | 128.54 |
| Days of Sales Outstanding | 181.97 | 140.01 | 84.26 | 56.72 | 36.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 233.07 | 189.38 | 184.19 |
| Days of Payables Outstanding | 48.66 | 34.63 | 82.37 | 62.25 | 91.65 |
| Operating Cycle | 181.97 | 140.01 | 317.33 | 246.10 | 220.19 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.51 | -6.83 | 0.92 | 1.15 | 6.48 |
| Free Cash Flow Per Share | -8.29 | -10.65 | 0.63 | -1.69 | 1.29 |
| Dividend Paid and CapEx Coverage Ratio | -0.22 | -1.79 | 3.10 | 0.39 | 1.25 |
| Capital Expenditure Coverage Ratio | -0.22 | -1.79 | 3.10 | 0.41 | 1.25 |
| Operating Cash Flow Coverage Ratio | -0.14 | -0.71 | 0.25 | 0.46 | 9.39 |
| Operating Cash Flow to Sales Ratio | -0.03 | -0.13 | 0.02 | 0.02 | 0.12 |
| Free Cash Flow Yield | -52.89% | -15.90% | 0.58% | -1.59% | 1.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 60.27 | 14.79 | -239.62 | 12.15 | 7.77 |
| Price-to-Sales (P/S) Ratio | 0.31 | 1.28 | 2.37 | 1.66 | 1.33 |
| Price-to-Book (P/B) Ratio | 0.34 | 1.60 | 2.84 | 3.05 | 3.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.89 | -6.29 | 173.50 | -62.74 | 54.46 |
| Price-to-Operating Cash Flow Ratio | -10.36 | -9.80 | 117.54 | 91.95 | 10.85 |
| Price-to-Earnings Growth (PEG) Ratio | -0.64 | -0.01 | 2.28 | -3.13 | 0.31 |
| Enterprise Value Multiple | 17.26 | 12.58 | 11.59 | 9.00 | 6.55 |
| Enterprise Value | 1.28B | 3.84B | 5.29B | 5.44B | 3.67B |
| EV to EBITDA | 17.26 | 12.58 | 11.59 | 9.00 | 6.55 |
| EV to Sales | 0.47 | 1.33 | 2.19 | 1.62 | 1.31 |
| EV to Free Cash Flow | -2.84 | -6.53 | 160.49 | -61.06 | 53.94 |
| EV to Operating Cash Flow | -15.59 | -10.17 | 108.73 | 89.50 | 10.74 |
| Tangible Book Value Per Share | 39.71 | 37.08 | 33.13 | 29.76 | 16.91 |
| Shareholders’ Equity Per Share | 45.71 | 41.92 | 38.23 | 34.72 | 21.49 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.73 | 0.13 | 2.18 | 0.19 | 0.13 |
| Revenue Per Share | 50.09 | 52.24 | 45.81 | 63.88 | 53.05 |
| Net Income Per Share | 0.26 | 4.53 | -0.45 | 8.73 | 9.05 |
| Tax Burden | 0.27 | 0.87 | -1.18 | 0.81 | 0.87 |
| Interest Burden | 1.00 | 1.00 | 0.05 | 0.97 | 0.98 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.27 | 0.16 | 0.12 | 0.09 | 0.05 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -5.82 | -1.51 | 2.41 | 0.11 | 0.63 |
Currency in INR

